Related Experiment Videos
[Treatment of blood circulation disorders with a hemoactive-vasoactive drug]
Insights
Fludilat effectively treats circulatory disorders, significantly improving symptoms like intermittent claudication and heaviness. This study highlights its excellent tolerance and efficacy in patients with atherosclerosis and diabetic vascular disease.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Circulatory disorders pose significant health challenges.
- Diabetic vascular disease and atherosclerosis are common underlying conditions.
Purpose of the Study:
- To evaluate the therapeutic activity of Fludilat in patients with circulatory disorders.
- To assess the efficacy and tolerance of Fludilat.
Main Methods:
- A study involving 20 patients (9 women, 11 men) aged 41-75.
- Patients had conditions including atherosclerosis and diabetic vascular disease.
- Symptom improvement was recorded for intermittent claudication, coldness, paresthesias, heaviness, and trophic changes.
Main Results:
- Significant symptom elimination observed: 71% for intermittent claudication, 67% for coldness, 46% for paresthesias, 73% for heaviness.
- Marked reduction in symptom intensity, except for trophic changes.
- Atherosclerotic patients showed a better response; no influence of age, sex, or blood pressure on outcomes.
Conclusions:
- Fludilat demonstrates excellent efficacy in treating various symptoms of circulatory disorders.
- The drug is well-tolerated with no significant side effects or changes in blood pressure.
- Fludilat is a valuable therapeutic option for patients with vascular conditions.
Abstract:
The therapeutic activity of Fludilat in circulatory disorders was evaluated in 9 women and 11 men, with ages between 41 and 75 years. Three suffered atherosclerosis and 17 diabetic vascular disease. Elimination of the symptom was obtained in intermittent claudication in 71 per cent of the patients who suffered it, in 67 per cent in case of feeling of coldness, in 46 per cent in paraesthesias, in 73 per cent in feeling of heaviness and in 6 per cent in trophic changes. In the remaining patients there was a significative reduction in the intensity of the symptoms, except in trophic changes. This result are considered as excellents. The general result of the treatment was satisfactory. There was no significacative change in the blood pressure and no side effects were reported. A better response of the atherosclerotic patients was obtained. We found no influence of age, sex and blood pressure on the results. The study corroborates the efficacy of Fludilat in the treatment of circulatory disorders and its excellent tolerance.